Orphazyme Aps, founded in 2009, develops paradigm-changing medicine for the treatment of a family of genetic disorders called lysosomal storage diseases. This family consists of more than 45 diseases, most of which are currently untreatable and often fatal. Lysosomal storage diseases affect mostly children who often die at a young and unpredictable age, many within a few years of birth. Other patients live longer, but ultimately die following years of suffering from defects in various organs such as the kidneys, liver, heart and CNS.
Orphazyme extends its seed financing by raising 22 mDDK from new investor Sunstone Capital as well as existing shareholder Novo A/S. In conjunction with the investment, Bo Jesper Hansen, Chairman of the board at public company Swedish Orphan Biovitrum, and Sten Verland, Partner Sunstone Capital, will join the board of directors. They add significant expertise and experience with the development and commercialization of orphan drugs.